Clinical Trial Update: TIL Therapy Combined With Pembrolizumab for Advanced Brain Cancer Including Gliomas and Meningiomas [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 clinical trial is evaluating the combination of tumor-infiltrating lymphocyte (TIL) therapy with pembrolizumab for advanced brain tumors, including …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Brain Cancer
• Brain Metastases
• Brain Tumor
• Glioblastoma
• Glioma
• Meningioma

Drugs mentioned

• Pembrolizumab (pembrolizumab)
• TIL therapy (tumor-infiltrating lymphocyte therapy)

Snippet

Sponsor: Essen Biotech | Conditions: Brain Tumor, Brain Metastases | Phase 1, Phase 2 | Status: RECRUITING